Advertisement
Advertisement
U.S. Markets open in 2 hrs 35 mins
Advertisement
Advertisement
Advertisement
Advertisement

Intellia Therapeutics, Inc. (NTLA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
44.60+1.45 (+3.36%)
At close: 04:00PM EST
45.30 +0.70 (+1.57%)
Pre-Market: 06:52AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close43.15
Open44.47
Bid0.00 x 1800
Ask0.00 x 800
Day's Range43.45 - 46.03
52 Week Range32.44 - 104.87
Volume1,622,196
Avg. Volume1,219,588
Market Cap3.319B
Beta (5Y Monthly)1.93
PE Ratio (TTM)N/A
EPS (TTM)-2.40
Earnings DateFeb 22, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est116.72
  • TheStreet.com

    Does Intellia Therapeutics Stock Have Good Genes?

    CRISPR editing firm Intellia Therapeutics was rated a new fundamental "overweight" (buy) by a sell-side firm Wednesday with a $67 price target. The On-Balance-Volume (OBV) line has been weak with a low just made in January. The weekly OBV line has struggled the past 18 months or so but may have made a low in January.

  • InvestorPlace

    7 CRISPR Stocks With the Best Long-Term Potential

    CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis. As a result, companies developing CRISPR-based products and services have seen significant valuation growth since inception, with many CRISPR stocks having excellent long-term upside potential in this regard. Several companies at the forefront of CRISPR technology have seen their stocks

  • InvestorPlace

    3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later

    To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editing to treat rare diseases is impressive. However, many gene editing stocks are making waves, looking to advance toward eradicating cancer and other serious illnesses. But ever since 2012, gene editing has been a reality, at least in terms of having the technology needed to edit genes. Don’t get me wr

Advertisement
Advertisement